Resveratrol in Chlamydia pneumoniae-induced foam cell formation and interleukin-17A synthesis

Journal of Biological Regulators and Homeostatic Agents

Volumn 27, Issue 2, 2013, Pages 509-518

  Di Pietro, M ^a   De Santis, F ^a   Schiavoni, G ^a   Filardo, S ^a   Sessa, Rosa ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Atherosclerosis; Chlamydia pneumoniae; Foam cells; IL 17A; Resveratrol

Indexed keywords

CHOLESTEROL; INTERLEUKIN 17; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESVERATROL; SUPEROXIDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; OXIDIZED LOW DENSITY LIPOPROTEIN; STILBENE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CHLAMYDOPHILA PNEUMONIAE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; ELISA KIT; ENZYME INHIBITION; FOAM CELL; IN VITRO STUDY; LIPID STORAGE; MACROPHAGE; NONHUMAN; OXIDATION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; METABOLISM; MOUSE; PATHOGENICITY; PHYSIOLOGY;

ANIMALS; CELLS, CULTURED; CHLAMYDOPHILA PNEUMONIAE; FOAM CELLS; INTERLEUKIN-17; LIPOPROTEINS, LDL; MICE; PPAR GAMMA; STILBENES; SUPEROXIDES;

EID: 84883479360     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Sessa R, Di Pietro M, Santino I, del Piano M, Varveri A, Dagianti A, Penco M. Chlamydia pneumoniae infection and atherosclerotic coronary disease. Am Heart J 1999; 137(6):1116-9. (Pubitemid 30040737)
2. Romano S, Fratini S, Di Pietro M, et al. Chlamydia pneumoniae infection in patients with acute coronary Syndrome: a clinical and serological 1-year follow-up. Int J Immunopathol Pharmacol 2004; 17(2):209-18.
3. Romano S, Penco M, Fratini S, Di Pietro M, Sessa R, del Piano M, Fedele F, Dagianti A. Chlamydia pneumoniae infection is associated with coronary artery disease but not implicated in inducing plaque instability. Int J Cardiol 2004; 95(1):95-9. (Pubitemid 38670478)
4. Sessa R, Di Pietro M, Schiavoni G, et al. Detection of Chlamydia pneumoniae in atherosclerotic coronary arteries. Int J Immunopathol Pharmacol 2004; 17:301-6. (Pubitemid 39481673)
5. Sessa R, Di Pietro M, Schiavoni G, et al. Chlamydia pneumoniae in asymptomatic carotid atherosclerosis. Int J Immunopathol Pharmacol 2006; 19:111-8.
6. Sessa R, Cipriani P, Di Pietro M, Schiavoni G, Santino I, del Piano M. Chlamydia pneumoniae and chronic diseases with a great impact on public health. Int J Immunopathol Pharmacol 2008; 21(4):1041-3.
7. Watson C, Alp NJ. Role of Chlamydia pneumoniae in atherosclerosis. Clin Sci Lond 2008; 114(8):509-31. (Pubitemid 351548759)
8. Schiavoni G, Di Pietro M, Ronco C, et al. Chlamydia pneumoniae infection as a risk factor for accelerated atherosclerosis in hemodialysis patients. J Biol Regul Homeost Agents 2010; 24(3):367-75.
9. Di Pietro M, Filardo S, Cazzavillan S, et al. Could past chlamydial vascular infection promote the dissemination of Chlamydia pneumoniae to the brain? J Biol Regul Homeost Agents 2013; 27(1):155-64.
10. Di Pietro M, De Santis F, De Biase D, Sessa R. The elusive but pathogenic peptidoglycan of Chlamydiae. Eur J Inflamm 2013; 11(1):257-60.
11. Di Pietro M, Schiavoni G, Sessa V, Pallotta F, Costanzo G, Sessa R. Chlamydia pneumoniae and osteoporosis associated bone loss: a new risk factor? Osteoporos Int 2013; 24(5):1677-82.
12. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997; 176(1):292-5. (Pubitemid 27272888)
13. Sessa R, Di Pietro M, Schiavoni G, Santino I, Cipriani P, Romano S, Penco M, del Piano M. Prevalence of Chlamydia pneumoniae in peripheral blood mononuclear cells in Italian patients with acute ischaemic heart disease. Atherosclerosis 2001; 159(2):521-5. (Pubitemid 33127267)
14. Sessa R, Di Pietro M, Schiavoni G, Santino I, Benedetti-Valentini F, Perna R, Romano S, del Piano M. Chlamydia pneumoniae DNA in patients with symptomatic carotid atherosclerotic disease. J Vasc Surg 2003; 37(5):1027-31. (Pubitemid 36538926)
15. Sessa R, Schiavoni G, Di Pietro M, et al. Chlamydia pneumoniae in PBMC: reproducibility of the ompA nested touchdown PCR. Int J Immunopathol Pharmacol 2005; 18:113-20. (Pubitemid 40343464)
16. Sessa R, Di Pietro M, Schiavoni G, et al. Measurement of Chlamydia pneumoniae bacterial load in peripheral blood mononuclear cells may be helpful to assess the state of chlamydial infection in patients with carotid atherosclerotic disease. Atherosclerosis 2007; 195(1):e224-30.
17. Deniset JF, Pierce GN. Possibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosis. Fundam Clin Pharmacol 2010; 24(5):607-17.
18. Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost 2011; 106(5):858-67.
19. Dogra J. Oral azithromycin in extended dosage schedule for chronic, subclinical Chlamydia pneumoniae infection causing coronary artery disease: a probable cure in sight? Results of a controlled preliminary trial. Int J Gen Med 2012; 5:505-9.
20. Sessa R, Nicoletti M, Di Pietro M, Schiavoni G, Santino I, Zagaglia C, del Piano M, Cipriani P. Chlamydia pneumoniae and atherosclerosis: current state and future prospectives. Int J Immunopathol Pharmacol 2009; 22(1):9-14.
21. Di Pietro M, Schiavoni G, del Piano M, et al. Chlamydia pneumoniae and atherosclerosis: the role of mast cells. J Biol Regul Homeost Agents 2009; 23(2):65-9.
22. Di Pietro M, Tramonti A, De Santis F, De Biase D, Schiavoni G, Filardo S, Zagaglia C, Sessa R. Analysis of gene expression in penicillin G induced persistence of Chlamydia pneumoniae. J Biol Regul Homeost Agents 2012; 26(2):277-84.
23. Mei CL, He P, Cheng B, Liu W, Wang YF, Wan JJ. Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR alpha and PPAR gamma-dependent pathways. Cell Biol Int 2009; 33(3):301-8.
24. Deby-Dupont G, Mouithys-Mickalad A, Serteyn D, Lamy M, Deby C. Resveratrol and curcumin reduce the respiratory burst of Chlamydia-primed THP-1 cells. Biochem Biophys Res Commun 2005; 333(1):21-7. (Pubitemid 40813441)
25. Kalayoglu MV, Miranpuri GS, Golenbock DT, Byrne GI. Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae. Microbes Infect 1999; 1(6):409-18.
26. Xu Q, Si LY. Resveratrol role in cardiovascular and metabolic health and potential mechanisms of action. Nutr Res 2012; 32(9):648-58.
27. Chen S, Shimada K, Zhang W, Huang G, Crother TR, Arditi M. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice. J Immunol 2010; 185(9):5619-27.
28. Sessa R, Di Pietro M, Schiavoni G, et al. Chlamydia pneumoniae induces T cell apoptosis through glutathione redox imbalance and secretion of TNF-alpha. Int J Immunopathol Pharmacol 2009; 22(3):659-68.
29. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
30. Lanzilli G, Cottarelli A, Nicotera G, Guida S, Ravagnan G, Fuggetta MP. Anti-inflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation. Inflammation 2012; 35(1):240-48.
31. Li H, Xia N, Förstermann U. Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide 2012; 15;26(2):102-10.
32. Pennings M, Meurs I, Ye D, Out R, Hoekstra M, Van Berkel TJ, Van Eck M. Regulation of cholesterol homeostasis in macrophages and consequences for atherosclerotic lesion development. FEBS Lett 2006; 580(23):5588-96. (Pubitemid 44465904)
33. Ye D, Lammers B, Zhao Y, Meurs I, Van Berkel TJ, Van Eck M. ATP-binding cassette transporters A1 and G1, HDL metabolism, cholesterol efflux, and inflammation: important targets for the treatment of atherosclerosis. Curr Drug Targets 2011; 12(5):647-60.
34. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27:485-517.
35. Eid RE, Rao DA, Zhou J, et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009; 119(10):1424-32.